GlaxoSmithKline announced on December 11th that the European Commission has approved the use of Dostarlimab (Jemperli) in combination with carboplatin and paclitaxel for the treatment of primary advanced or recurrent endometrial cancer carrying mismatch repair defects (dMMR) or high microsatellite instability (MSI-H).